





an Open Access Journal by MDPI

# **Novel Therapeutic Approaches for the Treatment of Neurodegenerative Diseases**

Guest Editors:

## Dr. Francesca Longhena

Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Viale Europa 11, 25123 Brescia, Italy

#### Dr. Valentina Straniero

Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, Via Luigi Mangiagalli, 25, 20133 Milan, Italy

Deadline for manuscript submissions:

30 November 2024

# **Message from the Guest Editors**

In the last two decades, the number of people living with neurodegenerative disorders has raised due to increased aging of world population, and their social and economic burden has become a major health issue. This notwithstanding, despite the great efforts dedicated to the identification new therapeutic targets and development of innovative disease-modifying agents, we still miss effective approaches able to halt or delay symptom progression and neurodegeneration in the brain of patients affected by these highly disabling conditions.

The aim of this Special Issue is to collect the latest research on novel therapeutic targets, as well as innovative deliveries or formulations, for the design pharmacological characterization of disease-modifying agents. counteracting neuronal loss. exerting neuroprotection or reducing pathological protein aggregates in neurodegenerative diseases.







IMPACT FACTOR 4.9





an Open Access Journal by MDPI

## **Editor-in-Chief**

#### Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

## **Message from the Editor-in-Chief**

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

#### **Contact Us**